Considering data from trials like MAINTAIN and the overall role of PIK3CA inhibitor use
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (July 13, 2025)
Would you still use the INAVO regimen for patients who relapse with P13K-mutated metastatic breast cancer on or shortly after use of adjuvant CDK4/6i? At first, one is tempted...